Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol (CBD) in Moderate to Severe Rheumatoid Arthritis
NCT04911127Phase 1Completed
- Sponsor
- University of California, Los Angeles
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cannabidiol in rheumatoid arthritis (RA) (3 arms), sponsored by University of California, Los Angeles. Primary endpoints: Disease Activity Score 28-joint count with Erythrocyte Sedimentation Rate at 12 weeks and Tolerability as assessed by participant attrition at 12 weeks. Started Oct 2021; status: completed.
02
Drugs
cannabidiol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04911127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04911127.